Skip to main content

InvestorNewsBreaks – TRxADE Health Inc. (NASDAQ: MEDS) Releases Q1 Financial Results

TRxADE Health (NASDAQ: MEDS), a health-services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, is reporting on its financial results for the quarter ended March 31, 2023. According to the report, the company is focused on continuing to expand its drug procurement marketplace nationwide, with an estimated 1,100 new members joining the platform during the first quarter of 2023, resulting in total registered members reaching more than 14,500 by quarter end. Financial numbers from the report show consolidated revenues for Q1 2023 decreased 31% to $2.2 million with gross profit analysis of comparable fiscal periods in both 2023 and 2022 reflecting an increase in gross profits of $221,000 for Q1 2023 compared to 2022. Operating expenses for the quarter reached $1.9 million with the company reporting a net loss of ($0.7) million compared to a net loss of ($1.0) million for same period in 2022. Adjusted EBITDA came in at ($0.06) million for the quarter 2023, compared to ($0.7) million for the first quarter 2022. “The first three months of 2023 have been an exciting and challenging time for TRxADE,” said TRxADE Health founder and CEO Suren Ajjarapu in the press release. “We continue to focus the company’s strategic plans and partnerships, working towards creating sustainable value for our stockholders. I am pleased with the growth we have experienced in our TRxADE platform. We continue to achieve key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities.”

To view the full press release, visit

About TRxADE Health Inc

TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug procurement marketplace serving more than 14,500 members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient-centric telehealth services. For more information about the company, please visit and

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.